title: Idiopathic pulmonary fibrosis - clinical management guided by the evidence-based GRADE approach: what arguments can be made against transparency in guideline development?
abstract: Evidence-based guidelines have undergone an incredible transformation over the last number of years. Significant advances include explicit linkages of systematic evidence summaries to the strength and direction of recommendations, consideration of all patient-important factors, transparent reporting of the recommendation generation process including conflict of interest management strategies and the production of clinical practice guidelines which use simple and clear language. The Grading of Recommendations Assessment, Development and Evaluation (GRADE) methodology provides a framework for guideline development and was employed to produce the recently published ATS/ERS/JRS/ALAT update on treatment for idiopathic pulmonary fibrosis (IPF). Herein we discuss the advantages of using an evidence-based approach for guideline development using the IPF process and resultant document as an example.
authors: Department of Medicine, McMaster University, Hamilton, ON, Canada. bram.rochwerg@gmail.com.|Department of Clinical Epidemiology & Biostatistics, McMaster University, Hamilton, ON, Canada. bram.rochwerg@gmail.com.
authors: Bram
authors: B
authors: Rochwerg
authors: Department of Medicine, McMaster University, Hamilton, ON, Canada. schuneh@mcmaster.ca.|Department of Clinical Epidemiology & Biostatistics, McMaster University, Hamilton, ON, Canada. schuneh@mcmaster.ca.
authors: Holger J
authors: HJ
authors: Schünemann
authors: Department of Medicine (Division of Pulmonary and Critical Care Medicine), University of Washington, Seattle, WA, USA. graghu@u.washington.edu.|Center for Interstitial lung Diseases, UW Medical Center, Seattle, WA, USA. graghu@u.washington.edu.
authors: Ganesh
authors: G
authors: Raghu
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D019468:Disease Management; D019317:Evidence-Based Medicine / Q000592:standards*; D006287:Health Planning Guidelines; D006801:Humans; D054990:Idiopathic Pulmonary Fibrosis / Q000188:drug therapy* / Q000517:prevention & control; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D017410:Practice Guidelines as Topic; D015272:Pulmonary Medicine / Q000592:standards*; D019141:Respiratory System Agents / Q000627:therapeutic use
chemical_list: D000911:Antibodies, Monoclonal; D007166:Immunosuppressive Agents; D019141:Respiratory System Agents